Edward Hurwitz
CIK 1211840 · last filed 2026-06-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$7.88M
Companies
6
Total Filings
50
Lifetime Open-Market Net
-$2.99M
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
Filer Profile
Related Filers
ALTA BIOPHARMA PARTNERS III LP — 16 joint filings, latest 2014-02-05
Farah Champsi — 16 joint filings, latest 2014-02-05
Edward Penhoet — 16 joint filings, latest 2014-02-05
ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG — 12 joint filings, latest 2014-02-05
ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC — 12 joint filings, latest 2014-02-05
Jean Deleage — 9 joint filings, latest 2010-10-27
Alix Marduel — 6 joint filings, latest 2008-09-05
Garrett Gruener — 4 joint filings, latest 2007-01-09
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DYN | Director | 91,081 | $15.45 | $1.41M | $0 | 7 | 2026-06-09 |
| MGNX | Director | 1,752,820 | $3.69 | $6.48M | -$11.19M | 18 | 2026-05-20 |
| APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | Director | 0 | $0.39 | $0 | $0 | 12 | 2022-12-01 |
| Tvardi Therapeutics, Inc. (CARA) Delisted | Director | 45,837 | $15.96 | $731.6K | $8.69M | 2 | 2014-02-05 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | Director | 582 | $18.62 | $10.8K | -$4.49M | 9 | 2013-07-02 |
| Molecular Templates, Inc. (THLD) Delisted | 139,693 | — | — | $4.00M | 1 | 2009-10-06 |
Recent Filings · Page 5 of 5
50 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-07-02 | Viracta Therapeutics, Inc. (SNSS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2011-07-05 | Viracta Therapeutics, Inc. (SNSS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2010-07-02 | Viracta Therapeutics, Inc. (SNSS) Delisted | Mixed | +16,909,694 | $3.28M | EDGAR |
| 2010-06-08 | Viracta Therapeutics, Inc. (SNSS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-12-16 | Viracta Therapeutics, Inc. (SNSS) Delisted | Sell (S) | −2,232,464 | -$4.49M | EDGAR |
| 2009-11-03 | Viracta Therapeutics, Inc. (SNSS) Delisted | Buy (P) | — | $0 | EDGAR |
| 2009-10-06 | Molecular Templates, Inc. (THLD) Delisted | Buy (P) | +2,094,240 | $4.00M | EDGAR |
| 2009-09-08 | — | Sell (S) | −6,460,533 | -$1.45M | |
| 2009-06-19 | Viracta Therapeutics, Inc. (SNSS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-04-07 | Viracta Therapeutics, Inc. (SNSS) Delisted | Grant (A) | — | $0 | EDGAR |
Showing 41–50 of 50
Prev
Page 5 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.